Diffuse large B-cell lymphoma trials in United Kingdom

In United Kingdom 13 Also abroad 346

13 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Aberdeen, Uxbridge
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
London, Nottingham, Plymouth, Southampton
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 2/3Taking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Aberdeen, London-Camden, Truro
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 2Taking people
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Where
Aylesbury, Birmingham, Bristol, Exeter, Lincoln, Liverpool, London, Manchester, Middlesbrough, Oxford, Plymouth
Age
18 years and over
People
594 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Birmingham, Cardiff, London, Newcastle upon Tyne, Sutton
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1Taking people
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Where
Leeds, Plymouth
Age
18 years and over
People
85 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Glasgow, Leeds, Liverpool, London, Manchester, Oxford, Plymouth, Southampton, Sutton
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
No phaseTaking people
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Where
Airdrie, Cheltenham, Manchester, Milton Keynes, Newcastle upon Tyne, Nottingham, Portsmouth, Truro
Age
18 years and over
People
700 worldwide
Run by
AbbVie
See details and how to joinNCT06830759
Phase 1Taking people
A Study of NX-1607 in Adults With Advanced Malignancies
Where
Cambridge, Glasgow, London, Manchester, Newcastle, Oxford, Sutton
Age
18 years and over
People
345 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05107674
No phaseNot yet taking people in United Kingdom
The Microbiome in Blood Cancer and HLH
Where
Nottingham
Age
16 years to 100 years
People
750
Run by
University of Nottingham
See details and how to joinNCT06734624
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Leeds, London, Southampton
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394